



A Weekly Member Update | September 10, 2026 | Page 1 of 2

Multi-Year Pharmacy Funding Framework Update

Dispensing Fee and Over-the-Counter (OTC) Product Pricing Changes

As previously announced in June 2026, a new multi-year Pharmacy Funding Framework was finalized. Through the summer, RxA has been working with Primary and Preventative Health Services (PPHS) and Alberta Blue Cross (ABC) to finalize the implementation and policy details for each component of the Pharmacy Funding Framework.

Starting October 1, 2026, the maximum allowable Dispensing Fee will increase from the current \$12.15 as follows:

- \$12.35 for days' supply of less than 84 days, and
- \$13.50 for days' supply of 84 days or greater.

Compounded products prepared in-store will continue to receive the current Dispensing Fee of \$18.45.

Over-the-counter (OTC) products will no longer receive a Dispensing Fee. OTC Products (Schedule 3) and Nutritional Products will be reimbursed at:

- MLP or LCAP + AU#1 (7.5%) + AU#2 (10% to max of \$100) + \$0 Dispensing Fee

Pricing for diabetic supplies will not be changing.

For more information, please refer to the [ABC Benefact link here](#).

As details are finalized on the remaining components of the Pharmacy Funding Framework, additional information will be communicated over the next few days and weeks.

The Results Are in for RxA's Board of Directors' Election

Congratulations to **Bob Sprague** and **Jill Mason**, who have been elected for the two open positions on RxA's 2026/2027 Board of Directors. Board members serve a three-year term, starting at the 2026 Annual General Meeting, which is scheduled to be held on Thursday, October 1.

Thank you to all the candidates for putting their names forward and RxA members for participating with your vote.

[Learn more about RxA's current board members here](#).

Community Based Naloxone Program Changes – October 1

Alberta Blue Cross has released an updated Benefact outlining changes to the Community-Based Naloxone (CBN) Program.

Effective October 1, 2026, a patient-specific Personal Health Number (PHN) must be recorded when submitting a claim for a Community Based Naloxone kit.

- The individual's PHN, full name, date of birth and gender must now be recorded for each kit provided.

- If an individual is unable or unwilling to provide a valid PHN, or does not have an active PHN, they should normally be referred to a [Community-Based Organization](#) (CBO) for access to a kit.
- The pseudo-PHN (NX00000000) may be used in limited specific circumstances, such as an immediate/emergency need or where an individual cannot access a PHN and no nearby CBO is available.
- Generally, one kit should be provided at a time on individual request, although additional kits may be provided when clinically indicated, to a maximum of five kits per individual per day.

Pharmacy teams should review [Alberta Blue Cross Benefact #1336](#) in full and ensure their pharmacy team and claiming processes are ready for the October 1 changes.

Government of Canada Public Consultation on AI Transparency

The Government of Canada has launched a public consultation on strengthening AI transparency as part of Canada's National Artificial Intelligence Strategy: AI for All. Increased transparency can help people understand when they are interacting with AI systems, help businesses make informed decisions about the AI products they adopt, and give governments and organizations the information they need to develop policies surrounding AI.

The consultation seeks input from Canadians and stakeholders on topics including:

- detecting and identifying AI-generated content
- helping individuals know when they are interacting with an AI system
- improving the availability of consistent and understandable information about AI systems, including their development, capabilities and limitations
- enabling the tracking of serious incidents related to AI systems
- advancing ways to better track the activity and interactions of AI agents

Public input will help inform Canada's next steps on AI transparency. The consultation is open until September 23, 2026.

Learn more and participate: <https://ised-isde.canada.ca/site/ised/en/have-your-say-advancing-ai-transparency-canada>

Member Benefit Spotlight: medSask Minor Ailment and Self-Care Guidelines

Did you know RxA members have exclusive access to **medSask Minor Ailment and Self-Care Guidelines**? medSask is a drug information service at the University of Saskatchewan, College of Pharmacy and Nutrition. The medSask Minor Ailment and Self-Care prescribing guidelines include over 30 guidelines. They are updated regularly and are being used by pharmacists nationally to support and document their prescribing activities. [RxA members can access this member benefit here!](#)

News

[Read the latest pharmacy news here.](#)